BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 17062665)

  • 21. Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Bandiera E; Rossi E; Donzelli C; Pasinetti B; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2007 Mar; 196(3):245.e1-11. PubMed ID: 17346539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma.
    Brenne K; Nymoen DA; Reich R; Davidson B
    Am J Clin Pathol; 2012 Feb; 137(2):240-7. PubMed ID: 22261449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
    Comin CE; Saieva C; Messerini L
    Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
    Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
    Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.
    May T; Virtanen C; Sharma M; Milea A; Begley H; Rosen B; Murphy KJ; Brown TJ; Shaw PA
    Gynecol Oncol; 2010 Apr; 117(1):9-17. PubMed ID: 20117829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma.
    Davidson B; Reich R; Lazarovici P; Flørenes VA; Risberg B; Nielsen S; Sert B; Bedrossian C
    Lung Cancer; 2004 May; 44(2):159-65. PubMed ID: 15084380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of müllerian origin?
    Gao FF; Krasinskas AM; Chivukula M
    Appl Immunohistochem Mol Morphol; 2012 May; 20(3):272-6. PubMed ID: 22498671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Major carcinogenic pathways identified by gene expression analysis of peritoneal mesotheliomas following chemical treatment in F344 rats.
    Kim Y; Ton TV; DeAngelo AB; Morgan K; Devereux TR; Anna C; Collins JB; Paules RS; Crosby LM; Sills RC
    Toxicol Appl Pharmacol; 2006 Jul; 214(2):144-51. PubMed ID: 16460773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions.
    Davidson B; Stavnes HT; Risberg B; Nesland JM; Wohlschlaeger J; Yang Y; Shih IeM; Wang TL
    Hum Pathol; 2012 May; 43(5):684-94. PubMed ID: 21937081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
    Davidson B
    Hum Pathol; 2016 Dec; 58():123-127. PubMed ID: 27589896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
    Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
    Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
    Deraco M; Nonaka D; Baratti D; Casali P; Rosai J; Younan R; Salvatore A; Cabras Ad AD; Kusamura S
    Ann Surg Oncol; 2006 Feb; 13(2):229-37. PubMed ID: 16444562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells.
    Cimino-Reale G; Gandellini P; Santambrogio F; Recagni M; Zaffaroni N; Folini M
    J Hematol Oncol; 2017 Jul; 10(1):140. PubMed ID: 28716051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
    Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
    Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.
    Yuan Y; Nymoen DA; Dong HP; Bjørang O; Shih IeM; Low PS; Trope' CG; Davidson B
    Hum Pathol; 2009 Oct; 40(10):1453-60. PubMed ID: 19454358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
    Lu KH; Patterson AP; Wang L; Marquez RT; Atkinson EN; Baggerly KA; Ramoth LR; Rosen DG; Liu J; Hellstrom I; Smith D; Hartmann L; Fishman D; Berchuck A; Schmandt R; Whitaker R; Gershenson DM; Mills GB; Bast RC
    Clin Cancer Res; 2004 May; 10(10):3291-300. PubMed ID: 15161682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma.
    Tabata C; Kanemura S; Tabata R; Masachika E; Shibata E; Otsuki T; Nishizaki T; Nakano T
    J Clin Gastroenterol; 2013 Sep; 47(8):684-8. PubMed ID: 23685846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Coordinately up-regulated genes in ovarian cancer.
    Hough CD; Cho KR; Zonderman AB; Schwartz DR; Morin PJ
    Cancer Res; 2001 May; 61(10):3869-76. PubMed ID: 11358798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis.
    Ljubimova JY; Lakhter AJ; Loksh A; Yong WH; Riedinger MS; Miner JH; Sorokin LM; Ljubimov AV; Black KL
    Cancer Res; 2001 Jul; 61(14):5601-10. PubMed ID: 11454714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.